DTCX Stock Price and Chart — NASDAQ:DTCX

This article provides detailed stock information for Datacentrex, Inc. (DTCX) on NASDAQ, including its current price, historical performance, market capitalization, and key financial metrics. It also offers technical analysis and answers frequently asked questions about the company's stock.

Original reporting
Published Mar 13, 2026, 9:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 13, 2026, 10:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
DTCX Stock Price and Chart — NASDAQ:DTCX — source image
Decision brief

The 30-second read

$DTCXNeutralLow
01

Why it matters

The article consolidates existing information without introducing new catalysts; thus, its impact on trading decisions is limited.

02

Market read

The article provides a broad overview suitable for investors seeking to understand DTCX's current standing but lacks immediate actionable signals.

03

What to watch

Potential upcoming earnings surprises or industry developments not covered in the article could alter the stock's trajectory.

Relevance 6/10Timing: short-term (days to weeks)

Background

DTCX is a NASDAQ-listed company operating in the technology sector, with recent focus on earnings and IPO activities.

Company-level read

Ticker impact

$DTCXNeutralMedium confidence
Context

Primary focus of the article, providing detailed stock information for Datacentrex, Inc. (DTCX) on NASDAQ.

Expected impact

Limited immediate impact; potential for moderate price movement depending on upcoming earnings and market sentiment.

Evidence & confidence

The article is informational with no clear directional bias or new material news that could significantly influence the stock price in the short term.

Market effects

The article's focus on technology and earnings topics suggests potential influence on sector sentiment, but no specific sector-wide signals are indicated.

Limited; as a NASDAQ-listed stock, the impact is primarily US-based.

Negligible; DTCX is a regional stock with limited global influence.

Counterpoint

While the article is neutral, some investors might interpret the detailed financial metrics as a sign of underlying strength, warranting a cautious bullish stance.

Key entities

  • Datacentrex, Inc.

    A technology company listed on NASDAQ, focusing on data center solutions.

  • NASDAQ

    Major US stock exchange where DTCX is listed.

Related articles

$DTCXMed

Datacentrex Reports Third Quarter 2026 Results and $30 Million Investment in Eagle LNG

Datacentrex, Inc. (DTCX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Datacentrex Reports Third Quarter 2026 Results and $30 Million Investment in Eagle LNG Eagle LNG’s established customer base and space propulsion capabilities create additional growth opportunities heading into 2027 ● Reports positive third-quarter Adjusted EBITDA of

$DTCXMed

Datacentrex Reports Second Quarter 2026 Financial Results

Datacentrex, Inc. (DTCX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Datacentrex Reports Second Quarter 2026 Financial Results; Ends Quarter with $51.9 Million in Cash and No Debt ● Revenue of $1.9 million and positive gross profit despite higher power costs and challenging digital asset market conditions ● GAAP net loss of $5.5 milli

$PALIMedAI 8/10

Palisade Bio doses first patient in ulcerative colitis trial

Palisade Bio (NASDAQ:PALI) dosed the first patient in its Phase 2b ASCENTRA-UC trial for ulcerative colitis. The company reported a Q3 2026 net loss of $14.6M, up from $2.9M in 2025. It has $113.6M in cash. The trial will enroll 204 patients, with results expected in Q4 2027. The company also plans a Phase 2a Crohn’s disease study, with enrollment starting in Q1 2027.

$IRMMed

Jefferies raises Iron Mountain stock price target on data center growth

Jefferies raised its price target on Iron Mountain (IRM) to $137 from $135, citing data center growth as a key driver. The stock is currently at $110.78, down 5% in a week but up 36.7% year-to-date. Jefferies projects data centers will contribute 20% of revenue by 2029, supporting 10% annual AFFO growth. Iron Mountain reported Q3 2026 earnings of $0.64 per share, beating estimates, with revenue up 13% year-over-year.

$NHPMedAI 9/10

NATIONAL HEALTHCARE PROPERTIES, INC. AND SUBSIDIARIES Unaudited Pro Forma Condensed Combined Financial Information

National Healthcare Properties, Inc. (NHP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 NATIONAL HEALTHCARE PROPERTIES, INC. AND SUBSIDIARIES Unaudited Pro Forma Condensed Combined Financial Information ( in thousands ) National Healthcare Properties, Inc. (including, as by context, National Healthcare Properties Operating Partnership, L.P. (the “OP”) a